The impact of positron emission tomography (PET) on expected management during cancer treatment

Cancer

Volumn 115, Issue 2, 2009, Pages 410-418

  Hillner, Bruce E ^a,g   Siegel, Barry A ^b   Shields, Anthony F ^c   Liu, Dawei ^d   Gareen, Ilana F ^d   Hanna, Lucy ^d   Stine, Sharon Hartson ^e   Coleman, R Edward ^f  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

^e AMERICAN COLLEGE OF RADIOLOGY   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cancer; Positron emission tomography; Prospective studies; Registry; Treatment monitoring

Indexed keywords

ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; HEALTH CARE POLICY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MEDICARE; METASTASIS; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; PATIENT MONITORING; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT CARE PLANNING; POSITRON-EMISSION TOMOGRAPHY; REGISTRIES;

EID: 59449088074     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24000     Document Type: Article

References (24)

1. Kelloff G J, Hoffman J M, Johnson B, et al. Progress and promise of FDG- PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785-2808.
2. Centers for Medicare and Medicaid Services. Publication 100-03: Medicare National Coverage Determinations. Transmittal 31; 2005. Available at: http://www.cms.hhs.gov/ transmittals/downloads/R31NCD.pdf. Accessed November 5, 2008.
3. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006; 354:496-507.
4. Weber W A. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983-995.
5. Lin L L, Mutic S, Low DA, et al. Adaptive brachytherapy treatment planning for cervical cancer using FDG-PET. Int J Radiat Oncol Biol Phys. 2007;67:91-96.
6. Lordick F, Ott K, Krause B-J, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805.
7. Centers for Medicare and Medicaid Services. Medicare National Coverage Determinations Manual, Chapter 1, pt 4 (Sections 200-310.1). Section 220.6.10. Available at: http://www.cms.hhs.gov/manuals/downloads/ncdl03cl-part4. pdf. Accessed November 5,2008.
8. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff. 2006;25:1218-1230.
9. Centers for Medicare and Medicaid Services. National Coverage Determinations with Data Collection as a Condition of Coverage: Coverage With Evidence Development. Document issued July 12, 2006. Available at: http://www. cms.hhs.gov/Transmittals/downloads/R956CP.pdf. Accessed November 5, 2008.
10. National Oncology PET Registry (NOPR). Available at: http:// www.cancerpetregistry.org/.Accessed November 5, 2008.
11. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155-2161.
12. Lindsay M J, Siegel BA, Tunis SR, et al. The National Oncologic PET Registry: expanded Medicare coverage for PET under coverage with evidence development. AJR Am J Roentgenol. 2007;188:1109-1113.
13. Hillner BE, Liu D, Coleman RE, et al. The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med. 2007;48:1901-1908.
14. Weber W A. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282-3292.
15. Holdsworth CH, Badawi RD, Manola JB, et al. C T and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Am J Roentgenol. 2007;189:W324-30.
16. MacManus MP, Seymour J F, Hicks R J. Overview of early response assessment in lymphoma with FDG- PET. Cancer Imaging. 2007;7:10-18.
17. Weber W A, Petersen V, Schmidt B, et al. Positron emission tomography in nonsmall- cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657.
18. American College of Radiology Imaging Network. Fludeox- yglucose [18F] PET / CT Scans in Patients with Stage IIIB or Stage IV Non-Small Cell Lung Cancer Undergoing Chemotherapy. ACRIN 6678. Available at: www. clinicaltrials.gov/ct2/show/NCT00424138. Accessed November 5, 2008.
19. European Organization for Research and Treatment of Cancer. Fludeoxyglucose [18F] PET Scan-Guided Therapy or Standard Therapy in Treating Patients with Previously Untreated Stage I or Stage II Hodgkin' Lymphoma. Available at: www.clinicaltrials.gov/ct2/show/NCT00433433. Accessed November 5, 2008.
20. Cancer and Leukemia Group B. Rituximab and Combination Chemotherapy in Treating Patients with Diffuse Large B- Cell Non- Hodgkin's Lymphoma. CALGB 50303. Available at: www.clinicaltrials.gov/ct2/show/NCT00118209.Accessed November 5, 2008.
21. Samson D, Flamm CR, Aronson N. FDG Positron Emission Tomography for Evaluating Breast Cancer. Blue Cross and Blue Shield Association; 2001:1-95. Available at: http://www.cms.hhs.gov/coverage/download/id71.pdf. Accessed November 5, 2008.
22. Hillner BE, Tunuguntla R, Fratkin M. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol. 2004;22:4147- 4156.
23. 18F fluorodeoxyglucose positron emission tomography in patients with nonsmall- cell lung cancer: a prospective study. J Clin Oncol. 2001;19:111-118.
24. Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluoro- deoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 2001;92:886-895.